Osteoarthritis (OA) is the most common form of arthritis in the world and is characterized by pain, various disabilities and loss of quality of life. Chondroitin sulfate (CS) is recommended as first-line therapy. CS of non-animal origin is of great interest for safety and sustainability reasons. This study aims to investigate the anti-inflammatory effects, anti-pain and ability-enhancement of a short-term supplementation with non-animal CS in overweight subjects with OA. In a randomized, double-blind, placebo-controlled pilot study, 60 overweight adults with symptomatic OA were allocated to consume 600 mg of non-animal CS (n = 30) or a placebo (n = 30) daily for 12 consecutive weeks. The assessment of knee-pain, quality of life, related inflammation markers and body composition was performed at 0, 4 and 12 weeks. The Tegner Lysholm Knee Scoring (TLKS) scale of the experimental group showed a statistically significant increase (+10.64 points; confidence interval (95% confidence interval (CI) 5.57; 15.70; p < 0.01), while the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score decreased (−12.24 points; CI 95% −16.01; −8.38; p < 0.01). The results also showed a decrease in the C-reactive protein (CRP) level (−0.14 mg/dL, CI 95% −0.26; −0.04; p < 0.01) and erythrocyte sedimentation rate (ESR) level (−5.01 mm/h, CI 95% −9.18; −0.84, p < 0.01) as well as the visual analogue scale (VAS) score in both knees. In conclusion, this pilot study demonstrates the effectiveness of non-animal CS supplementation in overweight subjects with knee OA in improving knee function, pain and inflammation markers.

Effectiveness of non-animal chondroitin sulfate supplementation in the treatment of moderate knee osteoarthritis in a group of overweight subjects: A randomized, double-blind, placebo-controlled pilot study / M. Rondanelli, V. Braschi, C. Gasparri, M. Nichetti, M.A. Faliva, G. Peroni, M. Naso, G. Iannello, D. Spadaccini, N. Miraglia, P. Putignano, T.A. Alalwan, S. Perna. - In: NUTRIENTS. - ISSN 2072-6643. - 11:9(2019), pp. 2027.1-2027.14. [10.3390/nu11092027]

Effectiveness of non-animal chondroitin sulfate supplementation in the treatment of moderate knee osteoarthritis in a group of overweight subjects: A randomized, double-blind, placebo-controlled pilot study

S. Perna
Ultimo
2019

Abstract

Osteoarthritis (OA) is the most common form of arthritis in the world and is characterized by pain, various disabilities and loss of quality of life. Chondroitin sulfate (CS) is recommended as first-line therapy. CS of non-animal origin is of great interest for safety and sustainability reasons. This study aims to investigate the anti-inflammatory effects, anti-pain and ability-enhancement of a short-term supplementation with non-animal CS in overweight subjects with OA. In a randomized, double-blind, placebo-controlled pilot study, 60 overweight adults with symptomatic OA were allocated to consume 600 mg of non-animal CS (n = 30) or a placebo (n = 30) daily for 12 consecutive weeks. The assessment of knee-pain, quality of life, related inflammation markers and body composition was performed at 0, 4 and 12 weeks. The Tegner Lysholm Knee Scoring (TLKS) scale of the experimental group showed a statistically significant increase (+10.64 points; confidence interval (95% confidence interval (CI) 5.57; 15.70; p < 0.01), while the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score decreased (−12.24 points; CI 95% −16.01; −8.38; p < 0.01). The results also showed a decrease in the C-reactive protein (CRP) level (−0.14 mg/dL, CI 95% −0.26; −0.04; p < 0.01) and erythrocyte sedimentation rate (ESR) level (−5.01 mm/h, CI 95% −9.18; −0.84, p < 0.01) as well as the visual analogue scale (VAS) score in both knees. In conclusion, this pilot study demonstrates the effectiveness of non-animal CS supplementation in overweight subjects with knee OA in improving knee function, pain and inflammation markers.
Inflammation; Knee osteoarthritis; Non-animal chondroitin sulfate; Obesity; Overweight; Pain; Absorptiometry; Photon; Adiposity; Aged; Anti-Inflammatory Agents; Biomarkers; C-Reactive Protein; Chondroitin Sulfates; Double-Blind Method; Female; Humans; Inflammation Mediators; Italy; Knee Joint; Male; Middle Aged; Osteoarthritis; Knee; Overweight; Pain Measurement; Pilot Projects; Quality of Life; Recovery of Function; Time Factors; Treatment Outcome; Dietary Supplements
Settore MED/49 - Scienze Tecniche Dietetiche Applicate
2019
Article (author)
File in questo prodotto:
File Dimensione Formato  
Rondanelli M - Nutrients 2019 - chondroitin sulfate.pdf

accesso aperto

Descrizione: Article
Tipologia: Publisher's version/PDF
Dimensione 707.4 kB
Formato Adobe PDF
707.4 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/956112
Citazioni
  • ???jsp.display-item.citation.pmc??? 9
  • Scopus 15
  • ???jsp.display-item.citation.isi??? 15
social impact